ClinicalTrials.gg
CompletedNCT00640510Updated Sep 2, 2009Results posted

A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia

A Phase 3 interventional study of Rapid Acting Intramuscular Olanzapine and Isotonic sodium chloride solution in Schizophrenia, sponsored by Eli Lilly and Company. Completed at 11 sites in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2009-09-02.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
75th of 94
34 · median 114
Started
2008
with 5 others
Phase 3
25 of 97
1 open now
Registered
54th of 97
by date
Lead sponsor
22 of 97
Eli Lilly and Company

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 75th largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2008, is one of 25 in phase 3, and was the 54th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The primary objectives of the study is to confirm if the efficacy of IM olanzapine in patients with schizophrenia is greater than IM placebo by comparing changes from baseline to 2 hours post first IM injection of agitation.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients have met Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia.
  • Male or female, at least 20 years and less than 65 years old.
  • Inpatients during the study.
  • Each patient, or a proxy consenter, understand the nature of the study and must sign an document. The patient is able to cooperate with all study procedures in the view of the investigator.
  • Patients are considered, by the investigator or subinvestigator, to be clinically agitated and appropriate candidates for treatment with intramuscular (IM) medication. The investigator must believe that it is safe to administer IM olanzapine to the patients with respect to the safety profile, including the anticholinergic properties of Olanzapine IM.
  • Patients have a minimum total score of ≧ 20 on the five items of the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) using the 1-7 scoring system prior to the first injection of study drug.
  • Patients have a score of 1 or 2 on the Agitation-Calmness Evaluation Scale (ACES) prior to the first injection of study drug.

Exclusion criteria

Exclusion Criteria:

  • Patients who were previously treated with oral olanzapine and are considered to be treatment-resistant to oral olanzapine, in the opinion of the investigator.
  • Patients who have a history of allergic reaction or intolerance to study medication.
  • Patients who show evidence of bradycardia or arrhythmia obtained either from a physical exam or an (ECG).
  • Patients who require concomitant treatment with any other medication with primary central nervous system activity, other than those allowed as specified in section "concomitant treatment".
  • Patients who have acute, serious or unstable medical conditions, including (but not limited to) hepatic insufficiency (specifically any degree of jaundice), recent cerebrovascular accidents, uncontrolled seizure disorders, serious acute systemic infection or immunologic disease, unstable cardiovascular disorders (including ischemic heart disease), renal, gastroenterologic, respiratory, endocrinologic, neurologic, or hematologic diseases.
  • Patients with inadequately controlled diabetes, or patients whose treatment for diabetes were changed within 4 weeks prior to the first injection of the study drug. The investigator's discretion will supersede even if the patients do not meet the above criteria for concurrent diabetes.
  • Patients who have a known or total of segmented cell and band cell counts of \<1,500 /millimeter cubed (mm3).
  • Patients who have a known /serum glutamic pyruvic transaminase (ALT/SGPT) values ≧2 times the normal upper limit of the performing laboratory () or aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) values ≧3 times the ULN or total values ≧1.5 times the ULN.
  • Patients who have a known serum triglycerides ≧500 milligrams/deciliter (mg/dL).
  • Electrocardiogram abnormalities considered clinically significant by the investigator.
  • Patients who have had treatment with injectable depot antipsychotics within one injection interval prior to study drug administration.
  • Patients who have received treatment with antipsychotics or other prohibited concomitant medicines showing in the section "prohibited concomitant medicines" within 2 hours prior to the first IM study drug administration.
  • Patients who have had treatment with benzodiazepines within 4 hours prior to first IM study drug administration.
  • Patients who have been administered epinephrine within 24 hours prior to the first IM study drug administration.
  • Patients who have received treatment with psychostimulants or reserpine within 7 days prior to the first IM study drug administration.
  • Patients who have received beta blockers or calcium channel blockers previously, must have been taking the same medication at the same dose for 28 days prior to the first IM study drug administration. No beta blockers or calcium channel blockers may be administered within 24 hours of the first IM study drug injection, or any time during the double blind phase.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    IM olanzapine 10mg

    Patients will receive at least one injection of Intramuscular (IM) olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).

    Drug: Rapid Acting Intramuscular Olanzapine

  • Placebo comparator
    IM placebo

    Patients will receive at least one injection of Intramuscular placebo. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).

    Drug: Isotonic sodium chloride solution

Interventions

  • 10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).

    Also known as: LY170053, olanzapine, RAIM

  • DrugIsotonic sodium chloride solution

    0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC)

    Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (Absent) to 7 (Extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

    Time frame: 2 hours post first intramuscular (IM) injection

Secondary outcomes

  1. Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC)

    Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (Absent) to 7 (Extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

    Time frame: 15 min, 30 min, 60 min, 90 min post first IM injection

  2. Number of Responders at 2 Hours After First Intramuscular (IM) Injection

    A responder was defined ast he patient with ≥ 40% decrease in the PANSS-EC total score at 2 hours after the first IM injection in comparison with baseline. (See outcome measure 1 for description of PANSS-EC).

    Time frame: 2 hours post first IM injection

  3. Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint

    The ACES differentiates agitation, calmness, and sleep-state, using a 9-point scale: 1 (Marked Agitation) to 9 (Unarousable). Scores of 4 (Normal) to 7 (Marked Calmness) were used for this outcome measure.

    Time frame: 30 min, 60 min, 90 min and 2 hours post first IM injection

07

Results

Posted Aug 26, 2009

Participant flow

Participant flow — Overall Study
MilestoneIM Olanzapine 10mgIM Placebo
Started1717
Completed1615
Not completed12
Withdrew: Lack of efficacy01
Withdrew: Protocol violation10
Withdrew: Physician decision01

Outcome measures

PrimaryChange From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC)

Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (Absent) to 7 (Extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

Time frame:
2 hours post first intramuscular (IM) injection
Reported as:
Mean · units on a scale
Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC)
units on a scaleIM Olanzapine 10mgIM Placebo
Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC)-4.7 ± 4.8-4.6 ± 4.5
Statistical analysis
  • IM Olanzapine 10mg vs IM Placebo · t-test, 2 sided · p = 0.940
SecondaryChange From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC)

Measures excitability and consists of the following 5 items from the PANSS: Excitement, Hostility, Tension, Uncooperativeness, and Poor Impulse Control. Each item is rated on a scale from 1 (Absent) to 7 (Extreme). The sum of the 5 items is defined as the PANSS-EC total score which ranges from 5 to 35.

Time frame:
15 min, 30 min, 60 min, 90 min post first IM injection
Reported as:
Mean · units on a scale
Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC)
units on a scaleIM Olanzapine 10mgIM Placebo
Change from Baseline to 15 minutes-1.2 ± 1.3-1.2 ± 1.5
Change from Baseline to 30 minutes-2.9 ± 2.8-2.4 ± 2.8
Change from Baseline to 60 minutes-3.8 ± 3.6-3.4 ± 4.1
Change from Baseline to 90 minutes-5.1 ± 4.3-4.6 ± 4.7
Statistical analysis
  • IM Olanzapine 10mg vs IM Placebo · t-test, 2 sided · p = 1.000 (P-value for Change from Baseline to 15 minutes. Change = Timepoint minus Baseline.)
  • IM Olanzapine 10mg vs IM Placebo · t-test, 2 sided · p = 0.620 (P-value for Change from Baseline to 30 minutes. Change = Timepoint minus baseline.)
  • IM Olanzapine 10mg vs IM Placebo · t-test, 2 sided · p = 0.784 (P-value for Change from Baseline to 60 minutes. Change = Timepoint minus baseline.)
  • IM Olanzapine 10mg vs IM Placebo · t-test, 2 sided · p = 0.756 (P-value for Change from Baseline to 90 minutes. Change = Timepoint minus baseline.)
SecondaryNumber of Responders at 2 Hours After First Intramuscular (IM) Injection

A responder was defined ast he patient with ≥ 40% decrease in the PANSS-EC total score at 2 hours after the first IM injection in comparison with baseline. (See outcome measure 1 for description of PANSS-EC).

Time frame:
2 hours post first IM injection
Reported as:
Number · participants
Number of Responders at 2 Hours After First Intramuscular (IM) Injection
participantsIM Olanzapine 10mgIM Placebo
Number of Responders at 2 Hours After First Intramuscular (IM) Injection34
Statistical analysis
  • IM Olanzapine 10mg vs IM Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint

The ACES differentiates agitation, calmness, and sleep-state, using a 9-point scale: 1 (Marked Agitation) to 9 (Unarousable). Scores of 4 (Normal) to 7 (Marked Calmness) were used for this outcome measure.

Time frame:
30 min, 60 min, 90 min and 2 hours post first IM injection
Reported as:
Number · participants
Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint
participantsIM Olanzapine 10mgIM Placebo
30 Minutes11
60 Minutes11
90 Minutes22
2 Hours32
Statistical analysis
  • IM Olanzapine 10mg vs IM Placebo · Fisher Exact · p = 1.000 (P-value for 30 Minutes.)
  • IM Olanzapine 10mg vs IM Placebo · Fisher Exact · p = 1.000 (P-value for 60 Minutes.)
  • IM Olanzapine 10mg vs IM Placebo · Fisher Exact · p = 1.000 (P-value for 90 Minutes.)
  • IM Olanzapine 10mg vs IM Placebo · Fisher Exact · p = 1.000 (P-value for 2 Hours.)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IM Olanzapine 10mg———
IM Placebo———
Most frequent other events
Most frequent other events
EventIM Olanzapine 10mgIM Placebo
Blood creatine phosphokinase increasedInvestigations0/171/16
Electrocardiogram T wave inversionInvestigations0/171/16
Blood glucose increasedInvestigations1/170/16
Blood pressure increasedInvestigations1/170/16
Glucose urine presentInvestigations1/170/16
ErythemaSkin and subcutaneous tissue disorders1/170/16

Baseline characteristics

Age Continuous
Age Continuous(years)IM Olanzapine 10mgIM PlaceboTotal
Mean47.4 ± 12.445.9 ± 11.546.7 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)IM Olanzapine 10mgIM PlaceboTotal
Female8614
Male91019
Region of Enrollment
Region of Enrollment(participants)IM Olanzapine 10mgIM PlaceboTotal
Japan171633
Diabetes Mellitus
Diabetes Mellitus(participants)IM Olanzapine 10mgIM PlaceboTotal
Yes224
No151429
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision Diagnosis
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision Diagnosis(participants)IM Olanzapine 10mgIM PlaceboTotal
Catatonic202
Disorganized7714
Paranoid7714
Undifferentiated101
Residual022
Pre-Therapy Antipsychotic Usage
Pre-Therapy Antipsychotic Usage(participants)IM Olanzapine 10mgIM PlaceboTotal
Yes (>=1000 milligrams/day)7613
Yes (<1000 milligrams/day)9918
No112
Age at Onset
Age at Onset(years)IM Olanzapine 10mgIM PlaceboTotal
Mean22.6 ± 6.421.3 ± 6.122.0 ± 6.2
Agitation-Calmness Evaluation Scale (ACES)
Agitation-Calmness Evaluation Scale (ACES)(units on a scale)IM Olanzapine 10mgIM PlaceboTotal
Mean1.8 ± 0.41.8 ± 0.41.8 ± 0.4

2 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukushima, 966-0902, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gunma, 377-0055, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kagoshima, 899-5652, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 234-0051, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 861-0002, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 716-0061, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okinawa, 904-0011, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saga, 842-0192, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 187-8551, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tottori, 682-0023, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yamagata, 999-2221, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2008
First posted
Mar 21, 2008
Start
Mar 2008
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Aug 26, 2009
Last update
Sep 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00640510
First posted
Mar 21, 2008
Start date
Mar 2008
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Aug 26, 2009
Last update
Sep 2, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion